{"entity":{"id":"nct07444541","kind":"trial","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Anova Innovation Limited, now recruiting.","summary":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07444541 by Anova Innovation Limited, with 84 participants planned, started 2026-08 and due to reach its primary completion in 2027-08. Interventions recorded: ANO31905, Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07444541","url":"https://clinicaltrials.gov/study/NCT07444541"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07444541","phase":"1/2","setting":"A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","sponsor":"Anova Innovation Limited","enrolled":84,"outcomes":[]},"route":"/trials/nct07444541/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}